TY - JOUR
T1 - A Novel Live-Attenuated Vaccine Candidate for Mayaro Fever
AU - Weise, William J.
AU - Hermance, Meghan
AU - Forrester, Naomi
AU - Adams, A. Paige
AU - Langsjoen, Rose
AU - Gorchakov, Rodion
AU - Wang, Eryu
AU - Alcorn, Maria D.H.
AU - Tsetsarkin, Konstantin
AU - Weaver, Scott C.
N1 - Funding Information:
This work was supported by a grant from the National Institute of Allergy and Infectious Disease (NIAID) through the Western Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research, National Institutes of Health (NIH) grant U54 AIO57156. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2014 Weise et al.
PY - 2014/8/7
Y1 - 2014/8/7
N2 - Mayaro virus (MAYV) is an emerging, mosquito-borne alphavirus that causes a dengue-like illness in many regions of South America, and which has the potential to urbanize. Because no specific treatment or vaccine is available for MAYV infection, we capitalized on an IRES-based approach to develop a live-attenuated MAYV vaccine candidate. Testing in infant, immunocompetent as well as interferon receptor-deficient mice demonstrated a high degree of attenuation, strong induction of neutralizing antibodies, and efficacy against lethal challenge. This vaccine strain was also unable to infect mosquito cells, a major safety feature for a live vaccine derived from a mosquito-borne virus. Further preclinical development of this vaccine candidate is warranted to protect against this important emerging disease.
AB - Mayaro virus (MAYV) is an emerging, mosquito-borne alphavirus that causes a dengue-like illness in many regions of South America, and which has the potential to urbanize. Because no specific treatment or vaccine is available for MAYV infection, we capitalized on an IRES-based approach to develop a live-attenuated MAYV vaccine candidate. Testing in infant, immunocompetent as well as interferon receptor-deficient mice demonstrated a high degree of attenuation, strong induction of neutralizing antibodies, and efficacy against lethal challenge. This vaccine strain was also unable to infect mosquito cells, a major safety feature for a live vaccine derived from a mosquito-borne virus. Further preclinical development of this vaccine candidate is warranted to protect against this important emerging disease.
UR - http://www.scopus.com/inward/record.url?scp=84921713602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921713602&partnerID=8YFLogxK
U2 - 10.1371/journal.pntd.0002969
DO - 10.1371/journal.pntd.0002969
M3 - Article
C2 - 25101995
AN - SCOPUS:84921713602
SN - 1935-2727
VL - 8
JO - PLoS neglected tropical diseases
JF - PLoS neglected tropical diseases
IS - 8
M1 - e2969
ER -